Koji Takagi
A5004312750- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Sepsis Diagnosis and Treatment
- Cardiac Arrest and Resuscitation
- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Cardiac pacing and defibrillation studies
- Electrolyte and hormonal disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pneumonia and Respiratory Infections
- Emergency and Acute Care Studies
- Chronic Disease Management Strategies
- Potassium and Related Disorders
- Antibiotics Pharmacokinetics and Efficacy
- Blood Pressure and Hypertension Studies
- Hemodynamic Monitoring and Therapy
- Neuropeptides and Animal Physiology
- Muon and positron interactions and applications
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Diabetes Treatment and Management
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Cardiac Fibrosis and Remodeling
- Pregnancy-related medical research
Momentum Research
2021-2025
University of Brescia
2023
Université Paris Cité
2019-2022
Inserm
2018-2022
Hôpital Lariboisière
2019-2022
Kawasaki Medical School
2021
French Clinical Research Infrastructure Network
2021
Nippon Medical School Musashi Kosugi Hospital
2017-2020
Assistance Publique – Hôpitaux de Paris
2020
Nippon Medical School
2014-2020
Abstract Aims STRONG-HF showed that rapid up-titration of guideline-recommended medical therapy (GRMT), in a high intensity care (HIC) strategy, was associated with better outcomes compared usual care. The aim this study to assess the role N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and its changes early during up-titration. Methods results A total 1077 patients hospitalized for acute heart failure (HF) >10% NT-proBNP decrease from screening (i.e. admission)...
STRONG-HF examined a high-intensity care (HIC) strategy of rapid up-titration guideline-directed medical therapy (GDMT) and close follow-up after acute heart failure (AHF) admission. We assess the role age on efficacy safety HIC.Hospitalized AHF patients, not treated with optimal GDMT were randomized to HIC or usual care. The primary endpoint 180-day death HF readmission occurred equally in older (>65 years, n = 493, 74 ± 5 years) younger patients (53 11 adjusted hazard ratio [aHR] 1.02, 95%...
The aim of this study was to evaluate efficacy and safety rapid up-titration guideline-directed medical therapies (GDMT) in men women hospitalized for acute heart failure (AHF).In STRONG-HF, AHF patients were randomized just prior discharge either usual care (UC) or a high-intensity (HIC) strategy GDMT up-titration. In these analyses, we compared the implementation, efficacy, HIC between women. population, 416/1078 (39%) By day 90, higher proportion both sexes group had been up-titrated full...
This analysis provides details on baseline and changes in quality of life (QoL) its components as measured by EQ-5D-5L questionnaire, well association with objective outcomes, applying high-intensity heart failure (HF) care patients acute HF.
Aims Biologically active adrenomedullin (bio‐ADM) is a promising marker of residual congestion. The STRONG‐HF trial showed that high‐intensity care (HIC) guideline‐directed medical therapy (GDMT) improved congestion and clinical outcomes in heart failure (HF) patients. association between bio‐ADM, decongestion, the effect size HIC GDMT remains to be elucidated. Methods results We measured plasma bio‐ADM concentrations 1005 patients within 2 days prior anticipated discharge (baseline) 90...
Abstract Aims Inflammation has emerged as a potential key pathophysiological mechanism in heart failure (HF) general and acute HF (AHF) specifically, with inflammatory biomarkers shown to be highly predictive of adverse outcomes these patients. The CORTAHF study builds on both data the fact that steroid burst therapy been effective treatment respiratory diseases COVID‐19. Our hypothesis is patients AHF elevated C‐reactive protein (CRP) levels without symptoms or signs infection, 7‐day course...
BackgroundSTRONG-HF demonstrated the safety and efficacy of rapid up-titration guideline-directed medical therapy (GDMT) with high intensity care (HIC) compared to usual in patients hospitalized for acute heart failure (HF). In HIC group, following indicators were used guide up-titration: estimated glomerular filtration rate [eGFR] <30ml/min/1.73m2, serum potassium >5.0 mmol/L, systolic blood pressure (SBP) <95mmHg, <55bpm, NT-proBNP concentration >10% higher than pre-discharge...
Abstract Aims Acute heart failure (AHF) impacts millions globally, with outcomes varying based on socio‐economic status (SES). Methods SES measured by annual household income, years of education and medical insurance coverage. Each patient's income level relative to the median or mean, respectively, in country was calculated, categorized into tertiles (0, 1 2 from lowest highest). scores (0–5) were computed as sum these levels plus coverage (0 = no yes ). Patients' baseline characteristics,...
Abstract Aims Patients hospitalized with acute heart failure (AHF) treated a 7 day prednisone course in the CORTAHF pilot trial had greater improvement health‐related quality of life (QoL) at Day both overall population and patients baseline interleukin 6 > 13 pg/mL. This post‐hoc analysis examines specific QoL domains relationship between clinical signs congestion QoL. Methods In trial, AHF high‐sensitivity C‐reactive protein (hsCRP) 20 mg/L were randomized 1:1 to once‐daily oral 40 mg...